1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oral Oncology Specialty Pharmacy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oral Oncology Specialty Pharmacy Market, by Drug Class
8.1.1 Targeted Therapies
8.1.1.1. Market Revenue and Forecast
8.1.2. Hormonal Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. Oral Chemotherapy
8.1.3.1. Market Revenue and Forecast
9.1. Oral Oncology Specialty Pharmacy Market, by Distribution Channel
9.1.1. PBM-Owned Specialty Pharmacies
9.1.1.1. Market Revenue and Forecast
9.1.2. Health System/Hospital-Owned
9.1.2.1. Market Revenue and Forecast
9.1.3. Independent & Retail Specialty
9.1.3.1. Market Revenue and Forecast
10.1. Oral Oncology Specialty Pharmacy Market, by Molecule Type
10.1.1. Branded Specialty Drugs
10.1.1.1. Market Revenue and Forecast
10.1.2. Specialty Generics
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class
11.1.2. Market Revenue and Forecast, by Distribution Channel
11.1.3. Market Revenue and Forecast, by Molecule Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class
11.1.4.2. Market Revenue and Forecast, by Distribution Channel
11.1.4.3. Market Revenue and Forecast, by Molecule Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class
11.1.5.2. Market Revenue and Forecast, by Distribution Channel
11.1.5.3. Market Revenue and Forecast, by Molecule Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class
11.2.2. Market Revenue and Forecast, by Distribution Channel
11.2.3. Market Revenue and Forecast, by Molecule Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class
11.2.4.2. Market Revenue and Forecast, by Distribution Channel
11.2.4.3. Market Revenue and Forecast, by Molecule Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class
11.2.5.2. Market Revenue and Forecast, by Distribution Channel
11.2.5.3. Market Revenue and Forecast, by Molecule Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class
11.2.6.2. Market Revenue and Forecast, by Distribution Channel
11.2.6.3. Market Revenue and Forecast, by Molecule Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class
11.2.7.2. Market Revenue and Forecast, by Distribution Channel
11.2.7.3. Market Revenue and Forecast, by Molecule Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class
11.3.2. Market Revenue and Forecast, by Distribution Channel
11.3.3. Market Revenue and Forecast, by Molecule Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class
11.3.4.2. Market Revenue and Forecast, by Distribution Channel
11.3.4.3. Market Revenue and Forecast, by Molecule Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class
11.3.5.2. Market Revenue and Forecast, by Distribution Channel
11.3.5.3. Market Revenue and Forecast, by Molecule Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class
11.3.6.2. Market Revenue and Forecast, by Distribution Channel
11.3.6.3. Market Revenue and Forecast, by Molecule Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class
11.3.7.2. Market Revenue and Forecast, by Distribution Channel
11.3.7.3. Market Revenue and Forecast, by Molecule Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class
11.4.2. Market Revenue and Forecast, by Distribution Channel
11.4.3. Market Revenue and Forecast, by Molecule Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class
11.4.4.2. Market Revenue and Forecast, by Distribution Channel
11.4.4.3. Market Revenue and Forecast, by Molecule Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class
11.4.5.2. Market Revenue and Forecast, by Distribution Channel
11.4.5.3. Market Revenue and Forecast, by Molecule Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class
11.4.6.2. Market Revenue and Forecast, by Distribution Channel
11.4.6.3. Market Revenue and Forecast, by Molecule Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class
11.4.7.2. Market Revenue and Forecast, by Distribution Channel
11.4.7.3. Market Revenue and Forecast, by Molecule Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class
11.5.2. Market Revenue and Forecast, by Distribution Channel
11.5.3. Market Revenue and Forecast, by Molecule Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class
11.5.4.2. Market Revenue and Forecast, by Distribution Channel
11.5.4.3. Market Revenue and Forecast, by Molecule Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class
11.5.5.2. Market Revenue and Forecast, by Distribution Channel
11.5.5.3. Market Revenue and Forecast, by Molecule Type
12.1. CVS Health (CVS Specialty / Caremark)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cigna (Evernorth / Accredo)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. UnitedHealth Group (OptumRx)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Walgreens Boots Alliance (AllianceRx / Walgreens Specialty)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Humana Pharmacy Solutions
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Prime Therapeutics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Biologics, Inc. Specialty Pharmacy
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Rite Aid Specialty Pharmacy
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Express Scripts Specialty Pharmacy
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Kroger Specialty Pharmacy
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
